Monthly Archives: April 2008

Apologies for light posting as of late. I’ve been buried deep in revisions to Building Biotechnology and prepping for an upcoming talk. Writing is coming to a close, so soon I’ll be looking for external reviewers and case study contributions.

For those of you attending BIO 2008, I’ll be presenting in a session on trends in biotechnology communication on Friday morning.

Title: Scientific Communications – Trends and Liabilities
Track: Public Relations/Investor Relations
Date and Time: Friday, June 20 9:00 AM – 10:30 AM

Looking forward to seeing old colleagues and meeting new friends BIO.

I’m also working on an interesting story I want to post on the blog shortly. It’s about the challenges of managing founder/board relations in building a biotechnology company. Stay tuned…

The March 2008 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract of each article:

Volume 14, Issue 2

Editorial

Editorial PDF
Yali Friedman

Articles

Export compliance for life sciences PDF
John Avellanet
A new approach to improve technology commercialisation in university medical schools PDF
Courtney Price, Richard Huston, Arlen D Meyers
Biotechnology business models work: Evidence from the pharmaceutical marketplace PDF
J Leslie Glick
Valuing biotechnology companies: Does classification by technology type help? PDF
Jacqueline Loh, Robert Brooks
Risk management for the biotechnology industry: A Canadian perspective PDF
Sandra Vanderbyl, Sherry Kobelak
Singapore’s biomedical sciences landscape PDF
Keat-Chuan Yeoh
Social responsibility for the use of genes, genomes and biotechnology in biotechnology companies: A commentary from the bioethical viewpoint PDF
Yoshihiro Okada, Kazuo N Watanabe

Legal and Regulatory Updates

Legal and regulatory update PDF
Gerry Kamstra, John Wilkinson

Conference Report

Maryland and Virginia unite at 2007 Mid-Atlantic Bio Conference PDF
Harley King

Book Reviews

Book Review: Stem cell wars: Inside stories from the Frontlines PDF
Grant H Skrepnek

 

Courtesy of DrugPatentWatch.com:

Drug Patent Expirations in April 2008
*Drugs may be covered by multiple patents

Tradename Applicant Generic Name Patent Number Patent Expiration
ACTINEX Univ Az Cancer Ctr masoprocol 4,695,590 APR 17,2008
ACTINEX Univ Az Cancer Ctr masoprocol 5,008,294 APR 15,2008
ESTROSTEP 21 Warner Chilcott ethinyl estradiol; norethindrone acetate 5,010,070 APR 23,2008
ESTROSTEP FE Warner Chilcott ethinyl estradiol; norethindrone acetate 5,010,070 APR 23,2008
FEMPATCH Parke Davis estradiol 5,006,342 APR 09,2008
LODINE XL Wyeth Pharms Inc etodolac 4,966,768 APR 30,2008
ORFADIN Swedish Orphan nitisinone 5,006,158 APR 09,2008
ZEMURON Organon Usa Inc rocuronium bromide 4,894,369 APR 13,2008

Courtesy of DrugPatentWatch.com